LAUSR

Durvalumab May Be Effective in Patients with EGFR+/ALK+ NSCLC.

Sign Up to like & get
recommendations!
1 Published in 2018 at "Cancer discovery"

DOI: 10.1158/2159-8290.cd-rw2018-049

Abstract: PD-L1 blockade with durvalumab achieves responses in patients with EGFR+/ALK+ and EGFR-/ALK- NSCLC. read more here.

Keywords: egfr alk; durvalumab may; alk nsclc; may effective ... See more keywords